Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
| ▸ | FURIN | P09958 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094809 | 1.00 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL20887781 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL23194271 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL21659206 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL23347003 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL24648759 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL24477196 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL24649271 | 0.96 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL23347004 | 0.95 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL23347041 | 0.95 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885OPRK1 3214/4885 |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885OPRK1 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.